International Myeloma Society 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: hematologists, medical oncologists, immunologists

+ Sample video: contact me for sample video

+ Information:

The 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop, hosted by the International Myeloma Society (IMS), is a specialized scientific convening held from March 27-28, 2026, at the Boston Marriott Long Wharf in Boston, MA. This workshop brings together leading clinical and experimental scientists to discuss the latest advancements, real-world data, and future directions of immune therapies for multiple myeloma. The program offers an in-depth exploration of CAR T cells, bispecific antibodies, resistance mechanisms, toxicity management, and novel in vivo approaches. It provides both in-person and on-demand access to scientific sessions, fostering global education and collaboration in the field.

Learning Objectives

Upon completion of this workshop, participants will be able to:

• Evaluate the latest clinical updates and real-world data for various CAR T cell therapies (Ide-cel, Cilta-cel, Anito-cel, GC012F) and bispecific antibodies (Teclistamab, Talquetamab, Elranatamab, Linvoseltamab).

• Analyze novel therapeutic approaches, including trispecific antibodies, combination therapies, and dual-targeted CAR T cells.

• Identify and manage toxicities associated with T cell engaging therapies, such as CAR-T-associated delayed neurotoxicity and immune effector cell enterocolitis.

• Understand the genomic drivers and microenvironmental factors contributing to response and resistance in BCMA and GPRC5D-targeted therapies.

• Apply practical strategies for optimizing the administration and sequencing of immune therapies in clinical settings.

Target Audience

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Best for hematologists, medical oncologists, immunologists, clinical researchers, and scientists.

Topics

• SESSION 1: CLINICAL UPDATES ON CART CELLS

  • Ide-cel and Cilta-cel: Latest Updates and Ongoing Trials

  • Latest Real World Data for CAR T Cells

  • Update on Anito-cel and GC012F

  • GPRC5D CAR T Cells: Latest Updates and Ongoing Trials

  • Dual-targeted CAR T Cell Approaches

  • Update on Allogeneic CAR T Cell Approaches

• SESSION 2: CLINICAL UPDATES ON BISPECIFIC ANTIBODIES

  • Teclistamab and Talquetamab for Relapsed MM: Latest Updates and Ongoing Trials

  • Elranatamab and Linvoseltamab for Relapsed MM: Latest Updates and Ongoing Trials

  • Real World Data for Bispecific Antibodies

  • Bispecific Abs for First-line and Maintenance Therapy

  • Etentamig and Cevostamab: Latest Updates and Ongoing Trials

• SESSION 3: NOVEL APPROACHES IN THE CLINIC

  • Trispecific Antibodies for Myeloma

  • Combining Bispecific Abs with CAR T Cells

  • Fixed Duration Bispecific Antibody Therapy

  • Augmenting T Cell Therapies with Proteasome Inhibitors

  • TriPRIL CAR T Cells

  • Bispecific with Anti-CD38 Antibody

• SESSION 4: TOXICITIES OF T CELL ENGAGING THERAPIES

  • Pre-treatment Parameters Predicting CAR T Cell Toxicities

  • Elevated ALC and CAR T Cell Toxicities

  • Managing CAR-T-associated Delayed Neurotoxicity

  • CAR T-related Lymphomas: Clinical and Mechanistic Insights

• SESSION 5: PRACTICAL CONSIDERATIONS FOR IMMUNE THERAPIES

  • Sequencing BCMA-directed Therapies: How to Choose?

  • Optimizing Outpatient Bispecific Ab and CAR T Cell Administration

  • Managing Extramedullary Disease with T cell-redirecting Therapies

  • T Cell Therapies for CNS Myeloma

  • Impact of CHIP on Outcomes after CAR T Cell Therapy

• SESSION 6: UNDERSTANDING RESPONSE AND RESISTANCE TO T CELL THERAPIES

  • Genomic Drivers of Resistance to BCMA-targeted Therapies

  • Mechanisms of Antigen Escape following GPRC5D-targeted Therapies

  • Immune Correlates of Response to BCMA CAR T Cells

  • Microenvironmental Factors Impacting Response/resistance

  • Immune Correlates of Resistance to Bispecific Antibodies

• SESSION 7: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 1

  • Evaluating Immune Fitness Across the Stages of MM Progression

  • Targeting S100A8/9 to Enhance T Cell Therapies

  • Overcoming T Cell Exhaustion

  • Modulating the Microbiome to Enhance CAR T Cell Therapy

• SESSION 8: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 2

  • Novel T Cell Therapy Targets for Myeloma

  • CAR T Cells Against CD70

  • Targeting Intra-cellular Targets

  • EZH1/2 inhibition to augment cellular therapy

  • Engingeering of First in Class CAR Bugs for Cancer Immunotherapy

• SESSION 9: CHALLENGING CASES IN IMMUNE EFFECTOR CELL THERAPY

  • CAR T Cell Therapy in a Patient with Plasma Cell Leukemia

  • Immune Effector Cell Enterocolitis: A Novel Clonal Lymphoproliferative Disorder?

  • Fatal HLH Following GPRC5D×CD3 Therapy: Lessons from Genetic and Infectious Co-factors

• SESSION 10: IN VIVO APPROACHES

  • Science of In Vivo CAR T Cell Therpay

  • Bedside CAR T Cell Production

  • In Vivo Bispecific Therapy

  • Clinical Results of In Vivo CAR T Cell Therapy

  • Clinical Results of In Vivo CAR T Cell Therapy Part II